Post Marketing Assessment of the Efficacy and Safety of Netromax (Netilmicin) in the Indian Pediatric Population.

Objective: A post-marketing study of Netilmicin (Netromax™) in Indian pediatric patients to assess the safety and efficacy of the drug in various susceptible infections. Method: The study was carried out by 129 pediatricians from across India in 10 states (Maharashtra, Delhi, Uttar Pradesh, Andhra Pradesh, Odisha, Chhattisgarh, Karnataka, Madhya Pradesh, West Bengal, and Bihar) from November 2011 to February 2012. A total number of 542 case report forms were collected and considered eligible for further analysis based upon the completeness of data. The disease profile of patients included bacteremia, septicemia (including neonatal sepsis), severe respiratory tract infections (RTI), intra-abdominal infections (including peritonitis), kidney and genitourinary tract infections, skin and soft tissue infections, burns, bone and joint infections, wounds and perioperative infections. Result: Demographic analysis showed the median age of patients to be 13 months and median duration of therapy was 5 days. Intravenous route (IV) (n= 340) was preferred over intramuscular route (IM) (n=202) by the physicians. Netilmicin was administered in the therapeutic dose range depending upon the age and severity of the condition. The results revealed a favorable clinical efficacy and safety profile of Netilmicin. Clinical Improvement was observed in 98% (n=532) of patients among whom, clinical resolution (Defined as the absence of the infection) was achieved in 63% (n=343) patients. Whereas, partial improvement (defined as partial disappearance of original symptoms and no further requirement of antibiotics) was observed in 35% (n=189) of patients. Adverse events were reported in 11% of the entire study population and were mild in nature. There was no serious adverse event reported during the study period. Conclusion: The present post-marketing study confirmed that at the given doses and duration of therapy, NetromaxTM exhibited remarkable antibacterial efficacy with no serious incidences of toxicity. Thereby giving evidence that NetromaxTM treatment is safe and effective among the Indian pediatric population.

Comparative Vestibulotoxicity of Different Aminoglycosides in the Guinea Pigs

The histopathological alterations in the vestibule due to aminoglycosides are well defined. Although there are reports comparing the vestibulotoxic effects of the many aminoglycosides, this is the first study to compare the effects of the most commonly used aminoglycosides i.e., streptomycin, gentamicin, amikacin and netilmicin administered both transtympanically and systemically. The transtympanic and systemic administration of each aminoglycoside caused similar histopathological alterations in the vestibule. The most severe degeneration in the cristae ampullaris, utriculus and sacculus was observed after streptomycine administration. The severity of the vestibular damage in terms of magnitude was in the order of streptomycine, gentamicin, amikacin, and netilmicin.

Comparación de sensibilidad bacteriana in vitro: amikacina versus netilmicina / Comparation of bacterial sensitivity in vitro: amikacin and netilmicin

Desde su introducción, los aminoglucósidos se han convertido en una parte importante del arsenal antimicrobiano empleado en el ámbito hospitalario. El propósito de este estudio fue comparar la sensibilidad in vitro de diferentes microorganismos frente a amikacina y netilmicina en el Hospital Universitario Dr. Manuel Núñez Tovar, durante 1996 y 1997. De manera general, la sensibilidad a ambos fármacos fue comparable, a excepción de ciertas variaciones para enterobacter sp. y serratia sp

Avaliaçäo de um novo aminoglicosídio netilmicina na prática clínica / Clinical evaluation of a new aminoglycoside-netilmicin in the clinical practice

Os autores estudaram o uso da netilmicina na terapêutica de ataque de infecçöes bacterianas agudas e, 30 pacientes, na dose de 150mg de 12 em 12 horas, durante 10 dias em média. Obtiveram 90% de cura nos casos tratados, sem a constataçäo de efeitos colaterais perceptíveis. Isso traduz um excelente desempenho da netilmicina, seu largo espectro de açäo a baixos níveis de toxicidade

Ensaio clínico com netilmicina: um novo aminoglicosídio semi-sintético de amplo espectro / Clinical trial with netilmicin: a new broad-spectrum semisynthetic aminoglicoside

Os autores pesquisaram o uso da netilmicina num total de 20 pacientes portadores de pneumonia, infecçäo urinária e infeccäo de tecidos moles, administrada por via intramuscular na dose de 150 mg a cada 12 horas, durante um período médio de 10 dias. Obtiveram excelentes resultados favoráveis evidenciando 95% de cura nos pacientes tratados, sem problemas de efeitos colaterais , uma vez que a tolerância do antibiótico foi muito boa